Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Details)

v3.10.0.1
Quarterly Financial Information (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]                    
Total revenues $ 1,685 [1] $ 896 [1] $ 2,255 [1] $ 463 [1] $ 5,357 [2] $ 36,183 [2] $ 10,890 [2] $ 260 [2] $ 5,299 $ 52,690
Restructuring (charge) credit (543) (909) (459)   4 29 (1,460) (2,020)    
Operating costs and expenses (4,564) (5,294) (4,787) (5,600) (7,371) (7,562) (8,119) (9,160) (22,156) (35,659)
(Loss) income from operations (3,422) (5,307) (2,991) (5,137) (2,010) 28,650 1,311 (10,920) (16,857) 17,031
Other income (expense), net 312 729 1,044 1,331 648 (600) (1,026) 205    
(Loss) income before income tax (3,110) (4,578) (1,947) (3,806) (1,362) 28,050 285 (10,715) (13,441) 16,258
Income tax (expense) benefit 98       44 (1,706)     98 (1,662)
Net (loss) income and comprehensive (loss) income $ (3,012) $ (4,578) $ (1,947) $ (3,806) $ (1,318) $ 26,344 $ 285 $ (10,715) $ (13,343) $ 14,596
Basic net (loss) income per share of common stock $ (0.35) $ (0.55) $ (0.23) $ (0.46) $ (0.16) $ 2.06 $ 0.02 $ (2.37) $ (1.59) $ 0.75
Diluted net (loss) income per share of common stock $ (0.35) $ (0.55) $ (0.23) $ (0.46) $ (0.16) [3] $ 1.98 [3] $ 0.02 [3] $ (2.37) [3] $ (1.59) $ 0.73
[1] Total revenues include upfront fees, milestone payments and royalties relating to various out-licensing arrangements, which includes $1.8 million of revenue recognized in the second quarter of 2018 under the license agreement and common stock purchase agreement with Rezolute, and $0.8 million in milestone revenue earned in the fourth quarter of 2018 under our license agreement with Janssen Biotech, Inc.
[2] In the third quarter of 2017, total revenues include upfront and milestone payments relating to various out-licensing arrangements, including $35.4 million of license fee revenue recognized in connection with the license agreements with Novartis, and, in the second quarter of 2017, total revenues include a $10.0 million milestone earned under the license agreement with Novartis International.
[3] For the quarters ended June 30, 2017 and September 30, 2017, the Company’s diluted net income per share of common stock was computed by giving effect to all potentially dilutive common stock equivalents outstanding during each of these periods.